Replies to post #296631 on Amarin Corp Plc (AMRN)

[bidmark]

JT is not a visionary. He’s an administrator.

[couldbebetter]

Europe is where AMRN could derive the highest value with Vascepa.
Actually, and more factually, it is where BP could derive the highest
value as regulatory exclusivity is 10 years from approval. Patents
could extend protection until 2039. That could be 18 years of sales!

Who do you think would be best able to optimize sales?:

1. AMRN's "team of experienced professionals?"

2. A BP such as Roche or Novartis?

Where should AMRN's stockpile of Vascepa be used?

1. Europe? (Where it could be priced as a branded Cardiovascular drug?)

2. US (Where generics could end up in a price war?)

Europe may be the golden opportunity for AMRN to attract a reasonable
BO deal. With each passing day the commercial life will be in decline.
If a BP launches Vascepa the right way, it should be a mega-blockbuster
drug there. If AMRN launches it instead...well, not so much.